Prognostic value of A/T/N biomarkers: Comparing plasma and imaging modalities in Alzheimer's disease | Synapse
March 3, 2026
Prognostic value of A/T/N biomarkers: Comparing plasma and imaging modalities in Alzheimer's disease
Key Points
The study reveals that imaging modalities provide a stronger prognostic value compared to plasma biomarkers in Alzheimer's disease.
Key evidence shows a significant difference in diagnostic accuracy, with imaging modalities outperforming plasma biomarkers in detecting neurodegeneration.
Assessment using plasma and imaging modalities identifies A/T/N biomarkers as critical predictors of Alzheimer's progression across diverse populations.
Findings highlight that while plasma biomarkers provide useful data, imaging modalities may offer superior insights into disease prognosis in Alzheimer’s patients.